reading up on this-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
Comment
Favorite

King Sean
04-24

reading up on this

Novo Shares Rise 6% While Lilly Falls over 4%. Lilly's New Obesity Pill Off to Slow Start in Race With Novo

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up...

Novo Shares Rise 6% While Lilly Falls over 4%. Lilly's New Obesity Pill Off to Slow Start in Race With Novo

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":557096956277856,"tweetId":"557096956277856","gmtCreate":1777041714702,"gmtModify":1777042124844,"author":{"id":4149940465171232,"idStr":"4149940465171232","authorId":4149940465171232,"authorIdStr":"4149940465171232","name":"King Sean","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>reading up on this</p></body></html>","htmlText":"<html><head></head><body><p>reading up on this</p></body></html>","text":"reading up on this","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/557096956277856","repostId":1104793495,"repostType":4,"repost":{"id":"1104793495","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1777041293,"share":"https://ttm.financial/m/news/1104793495?lang=en_US&edition=fundamental","pubTime":"2026-04-24 22:34","market":"us","language":"en","title":"Novo Shares Rise 6% While Lilly Falls over 4%. Lilly's New Obesity Pill Off to Slow Start in Race With Novo","url":"https://stock-news.laohu8.com/highlight/detail?id=1104793495","media":"Tiger Newspress","summary":"Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up...","content":"<html><head></head><body><p>Eli Lilly &amp; Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up with rival Novo Nordisk A/S.</p><p>Lilly shares fell 4.49% while Novo rose over 6%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d8612aa1621ba3ec177ad3ae8a47835c\" tg-width=\"540\" tg-height=\"180\"/></p><p style=\"text-align: start;\">Foundayo generated 3,707 prescriptions in its second week, according to IQVIA data cited by RBC Capital Markets analyst Trung Huynh. For comparison, an oral version of Novo’s Wegovy drew 18,410 prescriptions in its second week of launch.</p><p style=\"text-align: start;\">Lilly’s once-daily pill won US clearance earlier this month under a new program designed to expedite access to promising medications. The approval ratcheted up pressure on Novo, whose rival weight-loss pill — launched in January — has been key to its turnaround efforts.</p><p>Foundayo is being closely scrutinized by investors who see pills as the next frontier of weight-loss medicine. But until it’s been on the market for two to three months, factors such as sampling programs and the difficulty of capturing telehealth prescriptions will make it tougher to assess its true performance, Huynh said.</p><p style=\"text-align: start;\">“While we believe comparisons early into launch should be considered immaterial, Foundayo’s uptake this week is likely to be received negatively,” Huynh wrote in a note.</p><p style=\"text-align: start;\">Novo declined to comment. Lilly didn’t immediately respond to a request for comment.</p><p style=\"text-align: start;\">Beating Lilly on pills would give Novo a crucial leg up after the Danish drugmaker lost its early market leadership with injectable obesity drugs to its US rival. Lilly’s Zepbound outperformed Novo’s Wegovy on efficacy in a head-to-head trial.</p><p style=\"text-align: start;\">Yet when it comes to obesity pills, Novo may retain its lead because its oral Wegovy is a better product, Danske Bank analysts wrote in a note on Friday.</p><p style=\"text-align: start;\">While the pills haven’t been tested head to head, that hasn’t stopped the comparisons. In a large study from Lilly, Foundayo didn’t lead to the same level of weight loss that Novo showed in a separate trial of the Wegovy pill. Foundayo is easier to use with fewer restrictions, like taking it on an empty stomach and waiting 30 minutes before eating or drinking.</p><p style=\"text-align: start;\">Foundayo is a totally new drug. The Wegovy pill uses the same active ingredient, semaglutide, found in Novo’s injected Wegovy and in Ozempic.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Shares Rise 6% While Lilly Falls over 4%. Lilly's New Obesity Pill Off to Slow Start in Race With Novo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Shares Rise 6% While Lilly Falls over 4%. Lilly's New Obesity Pill Off to Slow Start in Race With Novo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2026-04-24 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Eli Lilly &amp; Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up with rival Novo Nordisk A/S.</p><p>Lilly shares fell 4.49% while Novo rose over 6%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/d8612aa1621ba3ec177ad3ae8a47835c\" tg-width=\"540\" tg-height=\"180\"/></p><p style=\"text-align: start;\">Foundayo generated 3,707 prescriptions in its second week, according to IQVIA data cited by RBC Capital Markets analyst Trung Huynh. For comparison, an oral version of Novo’s Wegovy drew 18,410 prescriptions in its second week of launch.</p><p style=\"text-align: start;\">Lilly’s once-daily pill won US clearance earlier this month under a new program designed to expedite access to promising medications. The approval ratcheted up pressure on Novo, whose rival weight-loss pill — launched in January — has been key to its turnaround efforts.</p><p>Foundayo is being closely scrutinized by investors who see pills as the next frontier of weight-loss medicine. But until it’s been on the market for two to three months, factors such as sampling programs and the difficulty of capturing telehealth prescriptions will make it tougher to assess its true performance, Huynh said.</p><p style=\"text-align: start;\">“While we believe comparisons early into launch should be considered immaterial, Foundayo’s uptake this week is likely to be received negatively,” Huynh wrote in a note.</p><p style=\"text-align: start;\">Novo declined to comment. Lilly didn’t immediately respond to a request for comment.</p><p style=\"text-align: start;\">Beating Lilly on pills would give Novo a crucial leg up after the Danish drugmaker lost its early market leadership with injectable obesity drugs to its US rival. Lilly’s Zepbound outperformed Novo’s Wegovy on efficacy in a head-to-head trial.</p><p style=\"text-align: start;\">Yet when it comes to obesity pills, Novo may retain its lead because its oral Wegovy is a better product, Danske Bank analysts wrote in a note on Friday.</p><p style=\"text-align: start;\">While the pills haven’t been tested head to head, that hasn’t stopped the comparisons. In a large study from Lilly, Foundayo didn’t lead to the same level of weight loss that Novo showed in a separate trial of the Wegovy pill. Foundayo is easier to use with fewer restrictions, like taking it on an empty stomach and waiting 30 minutes before eating or drinking.</p><p style=\"text-align: start;\">Foundayo is a totally new drug. The Wegovy pill uses the same active ingredient, semaglutide, found in Novo’s injected Wegovy and in Ozempic.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLII":"REX LLY Growth & Income ETF","NVO":"诺和诺德","ELIS":"1倍做空LLY ETF-Direxion","LLY":"礼来","LLYX":"2倍做多LLY ETF-Defiance","NVOH":"Novo Nordisk A/S B Shares ADRhedged","ELIL":"2倍做多LLY ETF-Direxion","LLYZ":"2倍做空LLY ETF-Defiance","NVOX":"2倍做多NVO ETF-Defiance"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104793495","content_text":"Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up with rival Novo Nordisk A/S.Lilly shares fell 4.49% while Novo rose over 6%.Foundayo generated 3,707 prescriptions in its second week, according to IQVIA data cited by RBC Capital Markets analyst Trung Huynh. For comparison, an oral version of Novo’s Wegovy drew 18,410 prescriptions in its second week of launch.Lilly’s once-daily pill won US clearance earlier this month under a new program designed to expedite access to promising medications. The approval ratcheted up pressure on Novo, whose rival weight-loss pill — launched in January — has been key to its turnaround efforts.Foundayo is being closely scrutinized by investors who see pills as the next frontier of weight-loss medicine. But until it’s been on the market for two to three months, factors such as sampling programs and the difficulty of capturing telehealth prescriptions will make it tougher to assess its true performance, Huynh said.“While we believe comparisons early into launch should be considered immaterial, Foundayo’s uptake this week is likely to be received negatively,” Huynh wrote in a note.Novo declined to comment. Lilly didn’t immediately respond to a request for comment.Beating Lilly on pills would give Novo a crucial leg up after the Danish drugmaker lost its early market leadership with injectable obesity drugs to its US rival. Lilly’s Zepbound outperformed Novo’s Wegovy on efficacy in a head-to-head trial.Yet when it comes to obesity pills, Novo may retain its lead because its oral Wegovy is a better product, Danske Bank analysts wrote in a note on Friday.While the pills haven’t been tested head to head, that hasn’t stopped the comparisons. In a large study from Lilly, Foundayo didn’t lead to the same level of weight loss that Novo showed in a separate trial of the Wegovy pill. Foundayo is easier to use with fewer restrictions, like taking it on an empty stomach and waiting 30 minutes before eating or drinking.Foundayo is a totally new drug. The Wegovy pill uses the same active ingredient, semaglutide, found in Novo’s injected Wegovy and in Ozempic.","news_type":1,"symbols_score_info":{"LLII":0.6,"NVOX":0.6,"LLYZ":0.6,"LLYX":0.6,"NVOH":0.6,"ELIS":0.6,"LLY":2,"ELIL":0.6,"NVO":2}},"isVote":1,"tweetType":1,"viewCount":380,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":15,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}